Even though Merck doesn’t plan an international marriage to cut its tax bill, its shares are rallying today on solid results in the latest quarter.
Merck�(MRK) stock is up 2% today after�Merck reported second-quarter earnings per share of 85 cents, better than the 81 cents analysts expected, according to Thomson I/B/E/S data.
Here are insights on the conference call that ensued, from�ISI’s biotech and pharmaceutical industry analyst�Mark Schoenbaum,�paraphrased:
Merck wants “bolt-ons” acquisitions (like Idenix Pharmaceuticals (IDIX)) versus big purchases. Moreover, it is not interested in a deal primarily or solely for tax inversion purposes … �[That's not ruling out the possibility of buying a foreign company to avoid U.S. taxes, but the language seems contrary to the foreign-merger possibilities for other healthcare companies, including�Valeant Pharmaceuticals (VRX), Actavis (ACT), Pfizer (PFE), AbbVie (ABBV), Medtronic (MDT) and even�Walgreen (WAG).] Merck sees a “high likelihood” of success for the four-week Hepatitis C regimen from C-SWIFT when presented at a medical conference this fall. (The combo treatment includes Gilead’s Sovaldi, already on the market, and a Merck regimen.) The company sees “lots of opportunities” to possibly accelerate Food & Drug Administration filings for an experimental immuno-oncology drug for lung cancer patients. It’s excited about the expected Aug. 14 FDA decision on insomnia drug Suvorexant. (Wall Street is bearish on commercial prospects.) Merck expects U.S. volume growth for diabetes drug Januvia (which is roughly 25% of earnings) in the second half of 2014.For healthcare investing ideas and insight on so-called tax inversions, see the Barrons.com Q&A with Andy Acker, manager of the Janus Global Life Sciences Fund (JAGLX): “Undervalued Biotech Stocks Help Fund Beat the Index,” July 29. (Subscription required) One insight from Acker:
10 Best Mid Cap Stocks To Watch Right Now: (BANC)
First PacTrust Bancorp, Inc. operates as a bank holding company for Pacific Trust Bank and Beach Business Bank that provides retail banking services to individuals and small to mid-sized businesses. The company offers various deposit accounts, such as checking and savings accounts, money market deposits, certificate accounts, retirement accounts, interest bearing demand accounts, and certificates of deposits. Its loan portfolio comprises commercial and industrial loans, commercial real estate mortgage loans, multi-family mortgage loans, small business administration guaranteed business loans, construction loans, lease financing, single family 1-4 unit residential mortgage loans, home equity lines of credit, home equity loans, and other consumer loans. In addition, the company offers leasing and financing services, cash and treasury management services, card payment services, remote deposit services, ACH origination, and employer/employee retirement planning products. Furth er, it provides mobile, online, and telephone banking services; automated bill payment services; electronic statements; safe deposit boxes; and direct deposit and wire transfers. As of December 31, 2012, it operated 19 banking offices in San Diego, Los Angeles, Orange, and Riverside counties in California; and 24 single family mortgage loan production offices in California, Arizona, Oregon, and Washington. First PacTrust Bancorp, Inc. was founded in 1941 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Markus Aarnio]
Banc of California (BANC) operates as a bank holding company for Pacific Trust Bank and Beach Business Bank that provides retail banking services to individuals and small to mid-sized businesses. Banc of California bottomed at $4.44 in December 2009 and is currently trading at $14.47 or 225.9% above the low made in December 2009. This performance is in line with the performance of the Financial Select Sector SPDR ETF.
Top 10 Life Sciences Stocks To Buy Right Now: Hot Topic Inc.(HOTT)
Hot Topic, Inc., together with its subsidiaries, operates as a mall- and Web-based specialty retailer in the United States. The company operates Hot Topic and Torrid store concepts, as well as an e-space music discovery concept, ShockHound. Its Hot Topic stores sell music/pop culture-licensed merchandise, including tee shirts, hats, posters, stickers, patches, postcards, books, novelty accessories, CDs, and DVDs; and music/pop culture-influenced merchandise comprising women?s and men?s apparel and accessories, such as woven and knit tops, skirts, pants, shorts, jackets, shoes, costume jewelry, body jewelry, sunglasses, cosmetics, leather accessories, and gift items for young men and women primarily between the ages of 12 and 22. The company?s Torrid stores sells casual and dressy jeans and pants, fashion and novelty tops, sweaters, skirts, jackets, dresses, hosiery, shoes, intimate apparel, and fashion accessories for various lifestyles for plus-size females primarily betw een the ages of 15 and 29. As of July 30, 2011, it operated 636 Hot Topic stores in 50 states, Puerto Rico, and Canada; 145 Torrid stores; and Internet stores, hottopic.com and torrid.com. The company was founded in 1988 and is headquartered in City of Industry, California.
Advisors' Opinion:- [By Marshall Hargrave]
In May True Religion (TRGL) announced a buyout offer from TowerBrook Capital for $826 million. Also in May, Rue21 decided to sell itself to Apax Partners for $2.2 billion. Before that, in March, Hot Topic (HOTT) announced that Sycamore Partners was buying out it out for $600 million.
Top 10 Life Sciences Stocks To Buy Right Now: Sagent Pharmaceuticals Inc.(SGNT)
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.
Advisors' Opinion:- [By Rich Smith]
Sagent Pharmaceuticals (NASDAQ: SGNT ) �is recalling three lots of Vecuronium Bromide for Injection, 10mg (NDC number 25021-657-10). Vecuronium Bromide for Injection is a neuromuscular blocking agent used in addition to general anesthesia to facilitate insertion of endotracheal tubes, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.�
- [By James Brumley]
In no particular order…
Sagent Pharmaceuticals (SGNT)Though Sagent Pharmaceuticals (SGNT) makes a few dozen generic drugs and has a similar number in the works, odds are good most investors couldn’t name a single one of them… and that’s a good thing for anyone on the hunt for cheap stocks from the pharma world.
- [By Roberto Pedone]
Sagent Pharmaceuticals (SGNT) is a pharmaceutical company engaged in developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. This stock closed up 1.1% at $23.58 in Thursday's trading session.
Thursday's Volume: 235,000
Three-Month Average Volume: 128,231
Volume % Change: 110%From a technical perspective, SGNT rose modestly higher here right above its 50-day moving average of $22.32 with above-average volume. This move pushed shares of SGNT into breakout territory, since the stock took out some near-term overhead resistance at $23.50. Shares of SGNT are now quickly moving within range of triggering another near-term breakout trade. That trade will hit if SGNT manages to clear its 52-week high at $24.27 with high volume.
Traders should now look for long-biased trades in SGNT as long as it's trending above its 50-day at $22.32 and then once it sustains a move or close above its 52-week high at $24.27 with volume that's near or above 128,231 shares. If that breakout hits soon, then SGNT will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $26.74 to its all-time high at $29.23.
Top 10 Life Sciences Stocks To Buy Right Now: MCG Capital Corporation(MCGC)
MCG Capital Corporation is a private equity firm specializing in investments in middle market companies. The firm does not prefer investments in highly cyclical and volatile industry sectors and businesses with significant volatility exposure. It seeks to invest in small to mid sized companies. The firm prefers to invest in acquisitions, growth financings, organic growth, recapitalization, and leveraged buyouts. It invests in companies based in the United States. The firm seeks to invest upto $75 million in debt and equity in companies having revenues between $20 million and $200 million and EBITDA between $3 million and $25 million. It seeks to invest in the form of senior debt, including amortizing, bullet maturity, term loans, and revolving credit facilities; institutional sub debt, including junior capital; second lien debt, that includes term loans on sole source and participant basis; secured and unsecured subordinate loans structured as current interest, deferred in terest, and equity linked components; mezzanine debt and equity that includes minority equity investments. The firm may invest in minority or control equity positions. It was formerly known as MCG Credit Corporation. MCG Capital Corporation was founded in 1990 and is based in Arlington, Virginia.
Advisors' Opinion:- [By Equities Lab]
The stocks that currently pass the stock screen in order of market cap are Frontier Communications Corp , Crown Media Holdings (CRWN), Vonage Holding (VG), MCG Capital Corp (MCGC), 1-800-FLOWERS.COM (FLWS), MTR Gaming Corporation (MNTG), Alaska Communications (ALSK), and Enzon Pharmaceuticals (ENZN).
Top 10 Life Sciences Stocks To Buy Right Now: Hibbett Sports Inc.(HIBB)
Hibbett Sports, Inc. operates sporting goods stores in small to mid-sized markets primarily in the southeast, southwest, Mid-Atlantic, and Midwest regions of the United States. Its stores offer an assortment of merchandise, including athletic footwear, team sports equipment, athletic and fashion apparel, and related accessories. The company also provides its merchandise directly to educational institutions and youth associations. As of January 28, 2012, it operated 832 stores consisting of 812 Hibbett Sports stores, 19 smaller-format Sports Additions athletic shoe stores, and 1 larger-format Sports & Co. superstore in 26 states. The company was formerly known as Hibbett Sporting Goods, Inc. and changed its name to Hibbett Sports, Inc. in January 2007. Hibbett Sports, Inc. was founded in 1945 and is headquartered in Birmingham, Alabama.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Hibbett Sports (Nasdaq: HIBB ) , whose recent revenue and earnings are plotted below. - [By Maria Armental and Tess Stynes var popups = dojo.query(".socialByline .popC"); ]
Hibbett Sports Inc.(HIBB) posted an 8.3% rise in fiscal first-quarter earnings, with the sporting-goods retailer saying it is benefiting from stronger demand in footwear and apparel.
- [By John Udovich]
Yahoo! Finance recently noted once again�how the hit reality show ��uck Dynasty��along with fears about Obama�� gun control policies have rural enthusiasts flocking to Cabela�� Inc (NYSE: CAB), but how does its performance compare with that of mid cap peer�Dicks Sporting Goods Inc (NYSE: DKS) along with small caps Big 5 Sporting Goods Corporation (NASDAQ: BGFV)�and Hibbett Sports, Inc (NASDAQ: HIBB)? After all, the same trends should be lifting all boats that sell outdoor related merchandise, guns or sporting goods (Note: Bass Pro, Inc, which is much closer to being a true�peer of Cabela�� Inc as its also focused on the outdoors, is�privately held) . �
Top 10 Life Sciences Stocks To Buy Right Now: Fluor Corporation(FLR)
Fluor Corporation, through its subsidiaries, provides engineering, procurement, construction, maintenance, and project management services worldwide. Its Oil & Gas segment offers design, engineering, procurement, construction, and project management services to upstream oil and gas production, downstream refining, chemicals, and petrochemicals industries. This segment also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies. The company?s Industrial & Infrastructure segment offers design, engineering, procurement, and construction services to the transportation, wind power, mining and metals, life sciences, manufacturing, commercial and institutional, telecommunications, microelectronics, and healthcare sectors. Its Government segment provides engineering, construction, logistics support, contingency response, management, and operations services to the United States government focusing on the Departme nt of Energy, the Department of Homeland Security, and the Department of Defense. The company?s Global Services segment offers operations and maintenance, small capital project engineering and execution, site equipment and tool services, industrial fleet services, plant turnaround services, temporary staffing services, and supply chain solutions. Its Power segment provides engineering, procurement, construction, program management, start-up and commissioning, and operations and maintenance services to the gas fueled, solid fueled, plant betterment, renewables, nuclear, and power services markets. The company also offers unionized management and construction services in the United States and Canada. Fluor Corporation was founded in 1912 and is headquartered in Irving, Texas.
Advisors' Opinion:- [By Ben Levisohn]
URS Corp, which competes with the likes of Fluor (FLR), Jacobs Engineering (JEC) and Tetra Tech (TTEK), said it would earn between $3.20 and $3.30 a share in 2013–the previous range had been between $4.10 and $4.25 a share–and also offered guidance for 2014 that was well below analyst forecasts. On the plus side, URS said it would buy its shares back at a faster pace than previously announced.
Top 10 Life Sciences Stocks To Buy Right Now: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.
The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.
CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.
Advisors' Opinion:- [By John Kell]
Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.
No comments:
Post a Comment